公开(公告)号：EP3077382A2

公开(公告)日：2016-10-12

申请号：EP14818867.5

申请日：2014-11-18

申请人： Merck Patent GmbH

发明人： PARHAM, Amir Hossain ,  BUESING, Arne ,  STOESSEL, Philipp ,  GERHARD, Anja ,  PFLUMM, Christof ,  EBERLE, Thomas ,  JATSCH, Anja ,  KROEBER, Jonas Valentin ,  DOBELMANN, Lars

IPC分类号： C07D313/06

CPC分类号： H01L51/0073 ,  A61N5/0616 ,  A61N2005/0653 ,  A61N2005/067 ,  C07D313/06 ,  C07D405/04 ,  C07D405/10 ,  C07D405/14 ,  C07D407/04 ,  C07D407/10 ,  C07D407/12 ,  C07D407/14 ,  C07D487/04 ,  C07D491/044 ,  C09K11/025 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1011 ,  C09K2211/1014 ,  C09K2211/1029 ,  C09K2211/1033 ,  C09K2211/1044 ,  C09K2211/1059 ,  C09K2211/1088 ,  C09K2211/185 ,  H01L51/0002 ,  H01L51/0003 ,  H01L51/0052 ,  H01L51/0053 ,  H01L51/0054 ,  H01L51/0056 ,  H01L51/0058 ,  H01L51/0059 ,  H01L51/006 ,  H01L51/0061 ,  H01L51/0067 ,  H01L51/0071 ,  H01L51/0072 ,  H01L51/0085 ,  H01L51/0087 ,  H01L51/5012 ,  H01L51/5016 ,  H01L51/5056 ,  H01L51/5072 ,  H01L51/5076 ,  H01L2251/5384 ,  Y02E10/549 ,  Y02P70/521

摘要： The invention relates to materials, to electroluminescence devices comprising said materials and to the use thereof.

摘要翻译： 本发明涉及包括所述材料的电致发光器件的材料及其用途。

公开(公告)号：EP2964645A4

公开(公告)日：2016-09-07

申请号：EP14760212

申请日：2014-03-08

申请人： SCINOPHARM TAIWAN LTD

发明人： HENSCHKE JULIAN P ,  CHEN YUE ,  HSIAO TSUNG YU

IPC分类号： C07D417/06 ,  C07D285/14 ,  C07D491/044

CPC分类号： C07D491/044

摘要： The present invention relates to a novel process of making ixabepilone, ixabepilone derivatives and analogues, and intermediates thereof.

摘要翻译： 本发明涉及一种制备伊沙匹隆，伊沙匹隆衍生物及其类似物的新方法及其中间体。

公开(公告)号：EP2921513A4

公开(公告)日：2016-08-17

申请号：EP13852931

申请日：2013-10-30

申请人： DAICEL CORP

发明人： INOUE HIROKO

IPC分类号： C08G59/20 ,  C07D209/48 ,  C07D491/044 ,  C08G59/02 ,  C08G59/24 ,  C08G59/26

CPC分类号： C08G59/26 ,  C07D209/48 ,  C07D491/044 ,  C08G59/02 ,  C08G59/20 ,  C08G59/24

摘要： An object of the present invention is to provide a novel epoxy compound capable of forming a highly heat-resistant cured product. The epoxy compound of the present invention is a compound represented by the following formula (1): wherein X 1 and X 2 are the same or different and represent an alkylene group, an oxygen atom, a sulfur atom, or no bond; R represents a bivalent group having one or more atoms; R 1 to R 8 are the same or different and represent a hydrogen atom, an alkenyl group which may have a substituent, an epoxidized alkenyl group which may have a substituent, or an alkyl group which may have a substituent; and Y 1 and Y 2 are the same or different and are a bivalent group represented by the following formula (a) : or a bivalent group represented by the following formula (b) : provided that least one of R 1 to R 12 in formula (1) is an alkenyl group which may have a substituent, an epoxidized alkenyl group which may have a substituent, or an alkyl group which may have a substituent. Besides, when both Y 1 and Y 2 in formula (1) are a bivalent group represented by formula (a), at least one of R 1 to R 10 is an epoxidized alkenyl group which may have a substituent.

公开(公告)号：EP2964645A1

公开(公告)日：2016-01-13

申请号：EP14760212.2

申请日：2014-03-08

申请人： Scinopharm Taiwan Ltd.

发明人： HENSCHKE, Julian P. ,  CHEN, Yue ,  HSIAO, Tsung, Yu

IPC分类号： C07D417/06 ,  C07D491/044 ,  C07D285/14

CPC分类号： C07D491/044

摘要： The present invention relates to a novel process of making ixabepilone, ixabepilone derivatives and analogues, and intermediates thereof.

公开(公告)号：EP2750678A1

公开(公告)日：2014-07-09

申请号：EP12826819.0

申请日：2012-08-29

申请人： PTC Therapeutics, Inc.

发明人： BRANSTROM, Arthur ,  JOSYULA, Vara Prasad, Venkata Nagendra ,  ARNOLD, Michael, Andrew ,  GERASYUTO, Aleksey, I. ,  KARP, Gary ,  WANG, Jiashi ,  CHEN, Guangming ,  GINZBURG, Olya ,  HUANG, Song ,  PEDDI, Srinivasa ,  WOLL, Matthew,G. ,  SMITH, Sean Wesley ,  ZHANG, Xiaoyan ,  ZHANG, Nanjing ,  TURPOFF, Antony Allan ,  NARASIMHAN, Jana

IPC分类号： A61K31/473

CPC分类号： C07D491/052 ,  A61K31/435 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/437 ,  A61K31/438 ,  A61K31/473 ,  A61K31/496 ,  A61K31/5377 ,  A61K31/55 ,  A61K45/06 ,  C07D221/10 ,  C07D221/14 ,  C07D221/16 ,  C07D401/04 ,  C07D471/04 ,  C07D471/14 ,  C07D491/044 ,  C07D491/048 ,  C07D491/14 ,  C07D495/04 ,  C07D519/00 ,  Y02A50/473 ,  Y02A50/475 ,  Y02P20/582 ,  A61K2300/00

摘要： The present description relates to compounds and forms and pharmaceutical compositions thereof and methods for use thereof to treat or ameliorate bacterial infections caused by wild-type and multi-drug resistant Gram-negative and Gram-positive pathogens.

摘要翻译： 本发明涉及化合物和形式及其药物组合物及其用于治疗或改善野生型和多重耐药性革兰氏阴性和革兰氏阳性病原体引起的细菌感染的方法。 本说明书还涉及对野生型和MDR细菌具有活性的化合物。 本说明书还涉及具有抗喹诺酮耐药革兰氏阴性菌株（包括MDR菌株）活性的化合物以及对耐MDR的革兰氏阳性病原体（包括MRSA菌株）的抗菌活性。

公开(公告)号：EP2660890A4

公开(公告)日：2014-05-21

申请号：EP11854396

申请日：2011-12-26

申请人： IDEMITSU KOSAN CO

发明人： NUMATA MASAKI

IPC分类号： H01L51/50 ,  C09K11/06

CPC分类号： H01L51/0072 ,  C07D471/04 ,  C07D491/044 ,  C07D495/04 ,  C07D519/00 ,  C07F7/0814 ,  C09K11/06 ,  C09K2211/1007 ,  C09K2211/1011 ,  C09K2211/1014 ,  C09K2211/1029 ,  C09K2211/1088 ,  C09K2211/1092 ,  H01L51/0071 ,  H01L51/0073 ,  H01L51/0085 ,  H01L51/5016 ,  H01L51/5056 ,  H01L51/5072

摘要： A material for organic electroluminescence device having a specific structure, in which an aromatic ring of a dibenzofuran skeleton, a carbazole skeleton, or a dibenzothiophene skeleton has a nitrogen atom as a heteroatom, and an organic electroluminescence device including an organic thin film layer which includes one or more layers between a cathode and an anode. The organic thin film layer includes a light emitting layer which includes a phosphorescent emitting material. At least one layer of the organic thin film layer includes the material for organic electroluminescence device. The organic EL device employing the material for organic EL device has a high external quantum efficiency even when driving the device at low voltage and also has a long lifetime.

公开(公告)号：EP2582704A4

公开(公告)日：2014-04-02

申请号：EP11796436

申请日：2011-06-16

申请人： REDDYS LAB LTD DR ,  REDDYS LAB INC DR

发明人： KATKAM SRINIVAS ,  POLAVARAPU SRINIVAS ,  YADDANAPUDI VENKATA MADHAVI ,  VINIGARI KRISHNA ,  PAGADALA NARASIMHA RAO ,  SAGYAM RAJESHWAR REDDY

IPC分类号： C07D491/044 ,  A61K31/407 ,  A61P25/18

CPC分类号： C07D491/04 ,  C07D491/044

公开(公告)号：EP2711368A1

公开(公告)日：2014-03-26

申请号：EP13193562.9

申请日：2010-09-27

申请人： F. Hoffmann-La Roche AG

发明人： Blaquiere, Nicole ,  Do, Steven ,  Dudley, Danette ,  Folkes, Adrian J. ,  Heald, Robert ,  Heffron, Timothy ,  Jones, Mark ,  Kolesnikov, Aleksandr ,  Ndubaku, Chudi ,  Olivero, Alan G. ,  Price, Stephen ,  Staben, Steven ,  Wang, Lan

IPC分类号： C07D498/04 ,  C07D498/14 ,  C07D519/00 ,  A61K31/4162 ,  A61K31/4188 ,  A61K31/4196 ,  A61P35/00

CPC分类号： C07D498/04 ,  A61K31/553 ,  A61K45/06 ,  C07D491/044 ,  C07D498/14 ,  C07D519/00

摘要： The invention relates to benzoxazepin compounds of Formula I

including stereoisomers, geometric isomers, tautomers, or pharmaceutically acceptable salts thereof, wherein: Z 1 is CR 1 or N; Z 2 is CR 2 or N; Z 3 is CR 3 or N; Z 4 is CR 4 or N; and B is a pyrazolyl, imidazolyl, or triazolyl ring which compounds have anti-cancer activity, and more specifically, inhibit PI3 kinase activity.

摘要翻译： 本发明涉及式I的苯并氧氮杂化合物，其包括立体异构体，几何异构体，互变异构体或其药学上可接受的盐，其中：Z 1为CR 1或N; Z 2为CR 2或N; Z 3为CR 3或N; Z 4为CR 4或N; 并且B是吡唑基，咪唑基或三唑基环，该化合物具有抗癌活性，更具体地，抑制PI3激酶活性。

公开(公告)号：EP2621898A4

公开(公告)日：2014-01-08

申请号：EP11827870

申请日：2011-09-26

申请人： ALPHORA RES INC

发明人： GORIN BORIS ,  DIXON CRAIG EDWARD ,  QU YANG

IPC分类号： C07D207/08 ,  C07C39/373 ,  C07D487/04 ,  C07D491/044 ,  C07D495/04

CPC分类号： C07D487/04 ,  C07C39/373 ,  C07D207/08 ,  C07D491/044

公开(公告)号：EP2582704A2

公开(公告)日：2013-04-24

申请号：EP11796436.1

申请日：2011-06-16

申请人： Dr. Reddy's Laboratories Ltd. ,  Dr. Reddy's Laboratories Inc.

发明人： KATKAM, Srinivas ,  POLAVARAPU, Srinivas ,  YADDANAPUDI, Venkata Madhavi ,  VINIGARI, Krishna ,  PAGADALA, Narasimha Rao ,  SAGYAM, Rajeshwar Reddy

IPC分类号： C07D491/044 ,  A61K31/407 ,  A61P25/18

CPC分类号： C07D491/04 ,  C07D491/044

摘要： Aspects of the present application relate to a microcrystalline monoclinic form of asenapine maleate represented by structural Formula (I); processes for its preparation; and pharmaceutically acceptable dosage forms thereof.